Navigation Links
Combination therapy reduced HER2-positive breast cancers
Date:12/10/2010

SAN ANTONIO A combination of lapatinib, trastuzumab and paclitaxel significantly improved tumor response rates than either agent alone among patients with HER2-positive breast cancers, according to data presented at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium, held Dec. 8-12. Full results were presented at the symposium during a press briefing on Dec. 10, 2010, at 8:00 a.m. CT.

Reporters who cannot attend in person can participate using the following call-in information:

  • U.S. and Canada: (888) 282-7404
  • International: (706) 679-5207
  • Access Code: 25346432

Lead researcher Jos Baselga, M.D., Ph.D., chief of the division of hematology and oncology and associate director of the Massachusetts General Hospital Cancer Center, said early data indicate a 50 percent rate of pathological complete remission compared with 20 percent for either agent alone.

"This study suggests that a dual blockade against HER2 is an efficient way to target HER2-positive breast tumors and that lapatinib adds to trastuzumab. While further research is ongoing, our results indicate that we are on the right track to improve the therapy of HER2-positive disease," said Baselga, who is also a founding editor-in-chief of the AACR's newest journal Cancer Discovery, along with Lewis C. Cantley, Ph.D.

These results are from the NeoALTTO Trial, an international, multicenter, randomized study comparing the efficacy of lapatinib plus paclitaxel vs. trastuzumab plus paclitaxel vs. a combination of all three agents as neoadjuvant chemotherapy among 455 patients with HER2-positive breast cancer.

"It has been suggested in basic science research and smaller clinical trials that the combination of these therapies would be more effective than either alone, but this is the first time it has been shown in a large clinical trial setting," said Baselga.

At the symposium, Baselga presented the primary outcome of tu
'/>"/>

Contact: Jeremy Moore
jeremy.moore@aacr.org
267-646-0557
American Association for Cancer Research
Source:Eurekalert

Page: 1 2

Related biology news :

1. Pertuzumab and trastuzumab combination improved efficacy for women with HER2-positive breast cancer
2. Novocure reports data showing TTF therapy in combination with chemotherapy has the potential to increase overall survival for patients with advanced non-small cell lung cancer
3. Grape news: New treatment combination safe alternative to sulfur dioxide
4. Study: Grass, fungus combination affects ecology
5. Investigators identify cleat/natural grass combination may be less likely to result in ACL injury
6. Diabetes drug kills cancer stem cells in combination treatment in mice
7. Old stain in a new combination
8. Phase III study compared neoadjuvant therapy with lapatinib or trastuzumab for early breast cancer
9. Early safety results promising for Phase I/II trial of gene therapy treatment of hemophilia B
10. Virginia Tech engineers introduce thermotherapy as a chemotherapy alternative
11. Never-smokers fare far better than smokers after radiation therapy for head and neck cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/13/2015)... TAIPEI , Feb. 13, 2015 ... service company that aims to transform cancer genomic ... announced that the company has raised US$ 8 million ... Based in Taipei, Taiwan ... tests, ACTDrug™, ACTOnco™. With the aim to implement ...
(Date:2/12/2015)... OXFORD, Conn. , Feb. 12, 2015 ... ("NXT-ID" or the "Company"), a biometric authentication company focused ... it has filed provisional patent 62/113114 for ... MULTIPLE DEVICES. The patent further establishes NXT-ID,s ... to its intellectual property portfolio the ability for multiple ...
(Date:2/10/2015)... Feb. 10, 2015  Alere Inc. (NYSE: ALR), ... financial results for the quarter ended December 31, ... and President of Alere said, "We made substantial ... as the global leader in rapid diagnostics and ... Alere Health divestiture in early January enabled us ...
Breaking Biology News(10 mins):ACT Genomics Raises $8 Million in its First Private Funding Round 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 3Alere Inc. Announces Fourth Quarter 2014 Results 2Alere Inc. Announces Fourth Quarter 2014 Results 3Alere Inc. Announces Fourth Quarter 2014 Results 4Alere Inc. Announces Fourth Quarter 2014 Results 5Alere Inc. Announces Fourth Quarter 2014 Results 6Alere Inc. Announces Fourth Quarter 2014 Results 7Alere Inc. Announces Fourth Quarter 2014 Results 8Alere Inc. Announces Fourth Quarter 2014 Results 9Alere Inc. Announces Fourth Quarter 2014 Results 10Alere Inc. Announces Fourth Quarter 2014 Results 11Alere Inc. Announces Fourth Quarter 2014 Results 12Alere Inc. Announces Fourth Quarter 2014 Results 13Alere Inc. Announces Fourth Quarter 2014 Results 14Alere Inc. Announces Fourth Quarter 2014 Results 15Alere Inc. Announces Fourth Quarter 2014 Results 16Alere Inc. Announces Fourth Quarter 2014 Results 17Alere Inc. Announces Fourth Quarter 2014 Results 18Alere Inc. Announces Fourth Quarter 2014 Results 19Alere Inc. Announces Fourth Quarter 2014 Results 20Alere Inc. Announces Fourth Quarter 2014 Results 21Alere Inc. Announces Fourth Quarter 2014 Results 22Alere Inc. Announces Fourth Quarter 2014 Results 23Alere Inc. Announces Fourth Quarter 2014 Results 24Alere Inc. Announces Fourth Quarter 2014 Results 25Alere Inc. Announces Fourth Quarter 2014 Results 26Alere Inc. Announces Fourth Quarter 2014 Results 27Alere Inc. Announces Fourth Quarter 2014 Results 28Alere Inc. Announces Fourth Quarter 2014 Results 29Alere Inc. Announces Fourth Quarter 2014 Results 30Alere Inc. Announces Fourth Quarter 2014 Results 31Alere Inc. Announces Fourth Quarter 2014 Results 32Alere Inc. Announces Fourth Quarter 2014 Results 33
... North American red foxes originated from two separate genetic ... half a million years ago, according to a U.S. Forest ... the April/May 2011 issue of Science Findings, a ... potentially imperiled montane populations of the species. "When ...
... research at UC Santa Barbara is contributing to the basic ... of the campus,s expanding vision research. The new studies ... of the National Academy of Sciences (PNAS), and ... document how they used mice as a research model organism ...
... Southampton is playing a key role in a major public/private ... cost effective and sustainable UK energy system for 2050. ... living organisms, such as plants, rubbish and wood), sustainably grown ... (1) of the UK,s energy needs by 2050 and significantly ...
Cached Biology News:Genetic study clarifies evolutionary origin of elusive montane red fox 2UCSB scientists make strides in vision research 2Southampton scientists to help create a sustainable energy system for the UK 2Southampton scientists to help create a sustainable energy system for the UK 3
(Date:2/27/2015)... 2015 Bionomics Limited (ASX:BNO, ADR:BMICY) is to ... BNC105 in patients with metastatic renal cancer at the ... . The data will be presented by Dr. ... Comprehensive Cancer Center in California ... data identifies Ferritin and IL-8 as two baseline biomarkers ...
(Date:2/27/2015)... South San Francisco, CA (PRWEB) February 27, 2015 ... it is joining forces on February 28 with patients ... globally to raise awareness for Rare Disease Day®. ... of rare diseases and calling attention to the special ... support community around them. , “Cytokinetics is proud to ...
(Date:2/26/2015)... NEW YORK , Feb. 26, 2015 ... commenced Factual Stock Report coverage on MabVax Therapeutics ... Inc. (MBVX) is a clinical stage biotechnology company focused ... address unmet medical needs in the treatment of cancer. ... products based on the protective immune responses generated by ...
(Date:2/26/2015)... - SQI Diagnostics Inc. ("SQI" or the "Company") (TSX-V: ... and commercializes proprietary technologies and products for advanced microarray ... the fiscal first quarter ended December  31, 2014. All ... (CAD), unless otherwise stated. "During the ... our existing customers and add to our sales pipeline," ...
Breaking Biology Technology:New BNC105 Biomarker Data to be Presented at US Cancer Conference 2New BNC105 Biomarker Data to be Presented at US Cancer Conference 3New BNC105 Biomarker Data to be Presented at US Cancer Conference 4New BNC105 Biomarker Data to be Presented at US Cancer Conference 5Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 2Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 3Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 4Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 5Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 6S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 5SQI Diagnostics Reports First Quarter Financial Results 2SQI Diagnostics Reports First Quarter Financial Results 3SQI Diagnostics Reports First Quarter Financial Results 4SQI Diagnostics Reports First Quarter Financial Results 5SQI Diagnostics Reports First Quarter Financial Results 6
... Stem Cell Innovations, Inc., (SCLL.PK) announced today that it has filed a ... germ cells. , ... Houston, TX (PRWEB) January 22, 2009 -- Stem ... patent application for the production of pluripotent stem cells from primordial germ ...
... Avantium Technologies announces the,launch of a new system ... will be marketed under the name,Crystalline. , ... the need in the pharma,industry to learn as much ... cycle. , "Avantium is proud ...
... Department of Chemistry at the University of Helsinki ... research agreement. ASM Microchemistry Ltd. is a subsidiary ... N.V. based in the Netherlands. The new agreement ... collaboration project started in 2004 and includes research ...
Cached Biology Technology:Stem Cell Innovations, Inc., Files New Patent Application 2Stem Cell Innovations, Inc., Files New Patent Application 3Avantium Launches the Crystalline, a New Parallel System for Crystallization Research 2University of Helsinki and ASM International renew research agreement on atomic layer deposition 2
Mouse polyclonal antibody to BTAF1 - BTAF1 RNA polymerase II, B-TFIID transcription factor-associated, 170kDa (Mot1 homolog, S. cerevisiae)...
... PHD2000 syringe pump series combines Harvard Apparatuss best ... and a wide range of configuration options. A ... dimensions of syringes from all the major manufacturers. ... all the pertinent information from across the lab. ...
ACS Reagent Grade C 19 H 14 O 5 S Formula Weight: 354.38 PRODUCT SPECIFICATIONS Form: Rust/red crystalline powder Clarity of Solution: Passes test Visual Transition Interval: pH 6.8 - Yellow pH 8.2...
... NTI allows you to store and manage ... in a secure central relational database. Storing ... an invaluable resource for clone tracking and ... for immediate analysis. LabShare software integrates seamlessly ...
Biology Products: